Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma Phase II Single Arm Study - Multicenter

NCT07128290 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT07128290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07128290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma Phase II Single Arm Study - Multicenter
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2025
Completion date
April 30, 2029
Enrollment
49 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma (icc)